-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Puli Pharmaceutical announced that the company recently received the marketing authorization for iopamidol injection issued by the Dutch Drug Evaluation Committ.
The product is mainly used in neuroradiology, including lumbar, thoracic and cervical spine, and CT spondylograp.
Contrast agent is a product injected/administered into human tissues or organs to enhance the effect of image observation, and is a common diagnostic and differential diagnosis drug in medical imagi.
In recent years, with the continuous increase in the number of patients with chronic diseases, major diseases, and neurological diseases, the demand for diagnosis has continued to expand, and the market size of contrast agents has continued to ri.
According to GrandViewResearch data, the global contrast agent market in 2021 has reached 04 billion US dolla.
, of which the United States accounted for nearly half, reaching 4
As a non-ionic, low-permeability iodinated contrast agent, iopamidol is widely used in various lumbar and cervical myelography, CT and CT-enhanced diagnostic fiel.
Iopamidol was originally developed by Brac.
It was approved for marketing in France as early as May 1981, and was subsequently approved for marketing in other European countri.
batch listi.
The iopamidol injection approved by the Netherlands this time is a generic drug, and it is also the first generic drug of contrast agent developed by the compa.
The successful approval this time marks that Puli Pharma has obtained the qualification to sell iopamidol injection in the Netherlands, and it also means that Puli Pharma can grab a market of over 20 billion contrast agents, which will have a positive impact on the company's market expansi.
It is reported that due to the impact of the epidemic, there is a shortage of contrast agents in Europe and the United Stat.
Puli Pharmaceutical stated that it will seize the production and export supply of iopamidol injection to provide high-quality contrast media for doctors and patients in Europe and the United States, and make up for the shortage of contrast media caused by the epidemic as soon as possib.
The company is successfully developing iopamid.
After the injection of generic drugs, the registration applications for generic drugs in China, Europe and the United States have been submitted respectively, which are collinear products; at the same time, the company will also speed up the research and development of other contrast agents in China, so that Chinese people can use the high-quality products exported to Europe and the United States as soon as possib.
contrast age.
As far as the Chinese market is concerned, the domestic consumption of contrast agents is far less than that of developed countri.
However, as the aging population increases, the prevalence of chronic diseases increases, and the level of consumption upgrades, the domestic market for contrast agents is also expandi.
In 2019, the sales of terminal contrast agents in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) have exceeded 15 billion yu.
At present, in the domestic contrast agent market, a large number of domestic and foreign pharmaceutical companies have been deployed, including Jiangsu Hengrui Medicine, General Electric, Yangzijiang Pharmaceutical Group, Bayer, Bracco, Chia Tai Tianqing, e.
Among them, Hengrui Medicine, General Electric, Yangzijiang The pharmaceutical group, Bayer, and Bracco have a relatively large market share in total, while the growth rate of Chia Tai Tianqing is relatively stro.
In the 2021 National Medical Insurance Drug List, two contrast media products, perfluorobutane microspheres for injection and perfluoropropane human albumin microspheres for injection, are includ.
In addition, in the fifth batch of centralized collection, iohexol The two varieties of injection and iodixanol injection won the bid, and the market of tens of billions made wav.
It is foreseeable that with the entry of more pharmaceutical companies, the competition in the domestic tens of billions of contrast media market will also become more inten.
At the same time, with the promotion of centralized procurement and consistency evaluation, the speed of product over-evaluation and price reduction will be affected to a certain exte.
te.
Click to enter the exhibition page
The product is mainly used in neuroradiology, including lumbar, thoracic and cervical spine, and CT spondylograp.
Contrast agent is a product injected/administered into human tissues or organs to enhance the effect of image observation, and is a common diagnostic and differential diagnosis drug in medical imagi.
In recent years, with the continuous increase in the number of patients with chronic diseases, major diseases, and neurological diseases, the demand for diagnosis has continued to expand, and the market size of contrast agents has continued to ri.
According to GrandViewResearch data, the global contrast agent market in 2021 has reached 04 billion US dolla.
, of which the United States accounted for nearly half, reaching 4
As a non-ionic, low-permeability iodinated contrast agent, iopamidol is widely used in various lumbar and cervical myelography, CT and CT-enhanced diagnostic fiel.
Iopamidol was originally developed by Brac.
It was approved for marketing in France as early as May 1981, and was subsequently approved for marketing in other European countri.
batch listi.
The iopamidol injection approved by the Netherlands this time is a generic drug, and it is also the first generic drug of contrast agent developed by the compa.
The successful approval this time marks that Puli Pharma has obtained the qualification to sell iopamidol injection in the Netherlands, and it also means that Puli Pharma can grab a market of over 20 billion contrast agents, which will have a positive impact on the company's market expansi.
It is reported that due to the impact of the epidemic, there is a shortage of contrast agents in Europe and the United Stat.
Puli Pharmaceutical stated that it will seize the production and export supply of iopamidol injection to provide high-quality contrast media for doctors and patients in Europe and the United States, and make up for the shortage of contrast media caused by the epidemic as soon as possib.
The company is successfully developing iopamid.
After the injection of generic drugs, the registration applications for generic drugs in China, Europe and the United States have been submitted respectively, which are collinear products; at the same time, the company will also speed up the research and development of other contrast agents in China, so that Chinese people can use the high-quality products exported to Europe and the United States as soon as possib.
contrast age.
As far as the Chinese market is concerned, the domestic consumption of contrast agents is far less than that of developed countri.
However, as the aging population increases, the prevalence of chronic diseases increases, and the level of consumption upgrades, the domestic market for contrast agents is also expandi.
In 2019, the sales of terminal contrast agents in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) have exceeded 15 billion yu.
At present, in the domestic contrast agent market, a large number of domestic and foreign pharmaceutical companies have been deployed, including Jiangsu Hengrui Medicine, General Electric, Yangzijiang Pharmaceutical Group, Bayer, Bracco, Chia Tai Tianqing, e.
Among them, Hengrui Medicine, General Electric, Yangzijiang The pharmaceutical group, Bayer, and Bracco have a relatively large market share in total, while the growth rate of Chia Tai Tianqing is relatively stro.
In the 2021 National Medical Insurance Drug List, two contrast media products, perfluorobutane microspheres for injection and perfluoropropane human albumin microspheres for injection, are includ.
In addition, in the fifth batch of centralized collection, iohexol The two varieties of injection and iodixanol injection won the bid, and the market of tens of billions made wav.
It is foreseeable that with the entry of more pharmaceutical companies, the competition in the domestic tens of billions of contrast media market will also become more inten.
At the same time, with the promotion of centralized procurement and consistency evaluation, the speed of product over-evaluation and price reduction will be affected to a certain exte.
te.
Click to enter the exhibition page
